Floatz logo

Idarubicine

Pediatric AML

Joanna YiPhase 3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Pediatric AML cohort.

Asset / SponsorPhaseRating
Mitoxantrone
Princess Maxima Center for Pediatric Oncology
Phase 3BB
Cladribine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3B
RH-ARG1-PEG-5,000 MW
University of Birmingham
Phase 1/2CCC
PREDNISOLONE SODIUM SUCCINATE
Joanna Yi
Early Phase 1C
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
Joanna Yi
Early Phase 1C
Epirubicin
Joanna Yi
Early Phase 1C
Pembrolizumab
Joanna Yi
Early Phase 1C

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →